HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study – In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.
A new weapon in the war against HIV-AIDS: Combined antiviral and targeted chemotherapy – HIV-AIDS could be treated through a combination of targeted chemotherapy and current Highly Active Retroviral (HAART) treatments, revealed by researchers.
Australian scientists develop a new low-cost, point-of-care HIV monitoring treatment – Scientists at the Burnet Institute, Australia’s leading medical research and public health institute focused on infectious diseases, have developed a prototype low-cost HIV monitoring test designed for field use in remote settings.
Millions of people infected with HIV may hope for healing promises, as a patient who has had undetectable HIV viral loads for almost two years after bone marrow transplant. – An HIV-positive person, who underwent a bone marrow transplant to treat leukemia, has had undetectable HIV viral loads for almost two years. HIV-positive man was ill from leukemia and had underwent treatment by the team led by Prof. Eckhard Thiel, director of the Medical Clinic with a focus on hematology and oncology.
Protein identified as TIM 3 that turns off HIV-fighting T cells in HIV positive patients sufferring from AIDS. – In HIV-infected patients the body’s immune system is unable to fight off the virus. A new study to be published online on November 10th in the Journal of Experimental Medicine shows that T cells in HIV-infected individuals express a protein called TIM-3, which inactivates their virus killing capacity.
Study suggests HIV infected patients should start highly active antiretroviral therapy (HAART) sooner. – Under current treatment guidelines, highly active antiretroviral therapy (HAART) should be considered for HIV-infected patients when their CD4+ T-cell counts fall below 350 cells per cubic millimeter (mm3).
Researchers from the Harvard School of Public Health (HSPH) estimate lives lost due to delay in antiretroviral drug use for HIV/AIDS in South Africa. – More than 330,000 lives were lost to HIV/AIDS in South Africa from 2000 and 2005 because a feasible and timely antiretroviral (ARV) treatment program was not implemented, assert researchers from the Harvard School of Public Health (HSPH) in a study published online by the Journal of Acquired Immune Deficiency Syndromes (JAIDS) (http://www.jaids.com/).
Antiretroviral therapy with TB treatment for HIV patients reduces mortality up to fifty five percent. – A South African treatment study conducted by researchers in the Department of Epidemiology at the Mailman School of Public Health shows that mortality among TB-HIV co-infected patients can be reduced by a remarkable 55%, if antiretroviral therapy (ART) is provided with TB treatment at the same time.
UA-led research indicates the HIV/AIDS pandemic began around 1900 in sub-Saharan Africa, decades earlier than first thought – New research indicates that the most pervasive global strain of HIV began spreading among humans between 1884 and 1924, suggesting that growing urbanization in colonial Africa set the stage for the HIV/AIDS pandemic.
Only 1% of people living with HIV/AIDS worldwide have been screened for tuberculosis, according to a report recently released by the coalition Advocacy To Control TB Internationally, or ACTION. – A mere 1% of people living with HIV/AIDS are reported to have been screened for TB, according to the most recent global data available from the World Health Organization. Health experts and activists at the International AIDS Conference are calling upon HIV/AIDS programs and international donors to ensure universal TB screening of every person who has tested positive for HIV.
